Modern life makes us tired, right? But research from societies in Africa and South America suggests people in the ancient ...

Speaking to China News Service, Pintos said his interest was sparked by last year’s Third Plenary Session of the 20th Central ...

智通财经APP获悉，Protagonist Therapeutics(PTGX.US)与武田(Takeda)今天宣布了3期研究VERIFY的初步积极结果。分析显示，该研究达到主要终点以及所有四个关键次要终点，其潜在“first-in-class”疗法rusfertide作为标准治疗的附加方案，使得近80%真性红细胞增多症(PV)患者不再需要接受放血治疗。 PV患者发生致命性心血管事件和血栓形成的风 ...